Cleveland BioLabs, Inc has received a Notice of Allowance from the US Patent and Trademark Office for its US Patent Application Number 11/421,918, titled 'Modulating Apoptosis'. Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502. This patent was already granted by the nine member countries of the Eurasian Patent Organization (EAPO) and two additional countries.

Cleveland BioLabs has filed 14 sets of patent applications in the US and internationally, around various aspects and properties for CBLB502 and related Protectan compounds, including methods of use and composition of matter.

Yakov Kogan, chief operating officer of Cleveland BioLabs noted, "We are extremely pleased to be receiving this patent coverage. Protectan CBLB502 represents a completely novel approach to protection of healthy tissues from the impact of radiation and other acute stresses. We continue to pursue additional claims under this and other patent applications both in the US and internationally."

CBLB502 is a derivative of a microbial protein, which has demonstrated the capacity to reduce injury from acute stresses, such as radiation and chemotherapy, in animal models.

Cleveland BioLabs, Inc is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses.